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Abstract
Pulmonary arterial hypertension (PAH) is a severe form of pulmonary hypertension that combines
multiple alterations of pulmonary arteries, including, in particular, thrombotic and plexiform lesions.
Multiple-pathological-insult animal models, developed to more closely mimic this human severe PAH
form, often require complex and/or long experimental procedures while not displaying the entire panel
of characteristic lesions observed in the human disease. In this study, we further characterized a rat model
of severe PAH generated by combining a single injection of monocrotaline with 4 weeks exposure to
chronic hypoxia. This model displays increased pulmonary arterial pressure, right heart altered function and
remodeling, pulmonary arterial inflammation, hyperresponsiveness and remodeling. In particular, severe
pulmonary arteriopathy was observed, with thrombotic, neointimal and plexiform-like lesions similar to
those observed in human severe PAH. This model, based on the combination of two conventional
procedures, may therefore be valuable to further understand the pathophysiology of severe PAH and
identify new potential therapeutic targets in this disease.
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Introduction
Pulmonary hypertension (PH) is a severe disease char-
acterized by sustained elevated mean pulmonary arter-
ial pressure (mPAP) over 25 mmHg, development of
right heart hypertrophy, leading to cardiac failure and
finally death [1]. Pathobiology of PH includes pul-
monary arterial inflammation, remodeling and altered
reactivity, all contributing to increased pulmonary
vascular resistances [2].
In the current PH classification, five groups have been
identified based on pathophysiological and clinical
considerations [1]. The pulmonary arterial hypertension
(PAH) group (Group 1) includes idiopathic or familial
forms of PH, as well as forms associated to other dis-
eases such as connective tissue diseases or HIV infection
[1, 3]. PAH is usually a severe form of PH that combines
multiple alterations of pulmonary arteries, including
thrombotic lesions, and/or complex and disorganized
lesions characterized by a network of proliferated chan-
nels separated by core cells, the so-called plexiform
lesions [4]. Current pharmacological treatments of PAH
manage to slow the progression of the disease but do
not afford a cure [5]. Since human samples are difficult
to obtain, pertinent animal models are therefore needed
to better understand PAH pathobiology and identify new
therapeutic targets. However, classical PAH animal
models do not recapitulate the severe pathology of hu-
man disease [6], and multiple-pathological-insult models
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have therefore been developed to mimic more closely
the human PAH pathophysiology. For instance, pneu-
monectomy has been associated to MCT injections,
leading to neointimal [7] or plexiform-like lesions [8]. In
other severe PAH models, SUGEN (SU5416, a tyrosine-
kinase inhibitor of the vascular endothelial growth factor
receptor VEGFR-2) has been associated to hypoxia [9, 10]
or pneumonectomy [11]. However, these models are time
consuming and/or require experimented manipulation for
surgical procedure.
Our group has developed an alternative rat model of
severe PAH, combining MCT injection to 3 weeks of
chronic hypoxia (Hx) [6]. Additional preliminary experi-
ments conducted in the same study on 4 rats suggested
the development of plexiform-like lesions when the
duration of Hx combined to MCT was increased to
4 weeks [6]. Herein, we aimed to confirm the interest of
this latter model based on a combination of two conven-
tional procedures: a single MCT intraperitoneal injection
associated to 4 weeks of Hx (MCT +Hx rats).
Description of the model
All animal studies were made according to European
and French directives about vertebrate animals protec-
tion use for animal experiments. Agreement was ob-
tained from French authorities (number A33-063-907)
and all the protocols used were approved by the local
ethics committee (Comité d’éthique regional d’Aquitaine,
protocol number: 50110016 A).
Male Wistar rats (250-350 g) were randomly assigned
into 5 groups: chronic hypoxia (Hx), monocrotaline
(MCT), severe PAH (MCT +Hx) for 3 or 4 weeks, and
controls (CTRL). Rats exposed to Hx were placed in a
hypoxic hypobaric chamber (380 mmHg) for 28 days
(4 weeks). In the MCT group, a single intraperitoneal
MCT injection (60 mg/kg, Sigma-Aldrich) was per-
formed at Day 1 and rats were maintained in a normo-
baric/normoxic environment (room air) for 28 days.
Severe PAH was induced by combining a single MCT
injection (60 mg/kg) at Day 1 with exposure to Hx from
Day 2 to Day 28, as previously described [6, 12]. This























































































Fig. 1 Evaluation of pulmonary arterial hypertension by measuring mean pulmonary arterial pressure, right cardiac remodeling and function, and
pulmonary arteries secretion of inflammatory cytokines. a Mean pulmonary arterial pressure (mPAP in mmHg) measured in controls rats (CTRL),
after 4 weeks of chronic hypoxia (Hx), after 4 weeks of monocrotaline injection (MCT) or after combination of MCT and 3 or 4 weeks of Hx (3wk
or 4wk MCT + Hx). Data represent means ± SEM with n = 13–14 rats per group. ***p < 0.001 versus controls. b Right ventricular hypertrophy
expressed as the Fulton index (= Ratio of right ventricle weight (RV) to left ventricle plus septum weight (LV + S)) in the same experimental
groups. Data represent means ± SEM with n = 14–15 rats per group. ***p < 0.001 versus controls and ##p < 0.01 versus Hx. c Right heart ejection
fraction (EF%) in CTRL or after combination of MCT and 3 or 4 weeks of Hx. Data represent means ± SEM with n = 6–8 rats per group. **p < 0.01
versus controls. d-e Secretion of the pro-inflammatory cytokines interleukin-1β (IL-1β, d) and tumor necrosis factor-α (TNF-α, e) by pulmonary
arteries in control rats (CTRL), after chronic hypoxia (Hx), after monocrotaline treatment (MCT), or in rats treated with MCT and exposed to 4 weeks
of Hx (4 wk MCT + Hx). Cytokines were determined by ELISA (results expressed as pg cytokine/ml supernatant after 24 h of incubation in the
culture medium and presented as a percentage of cytokine secretion compared to controls). Data represent means ± SEM with n = 6 rats per
group. **p < 0.01 and ***p < 0.001 versus controls. For all experiments, determination of statistically significant differences was assessed with a
one-way analysis of variance followed by a Dunn test
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combined model was also studied at 1, 2 or 3 weeks of
chronic hypoxia. Control rats were injected with MCT
vehicle and maintained in a normobaric/normoxic en-
vironment (room air) for 28 days. Hypobaric cham-
bers were opened three times a week for animal care
and cleaning, and all animals had free access to food
and water.
For details about other methods and statistical ana-
lysis, see the online supplemental methods section.
Findings
By assessing direct mPAP measurements, as previously
described [12], we show, for the first time, in MCT +Hx
rats, significant increased mPAP values compared to
controls after 3 or 4 weeks of our protocol (Fig. 1a).
These hemodynamic changes were in accordance with
previous studies showing significant increase in right
ventricle systolic pressure in this model [6, 13]. Together
with increased mPAP values, right ventricular hyper-
trophy is another hallmark of PH, and we confirm, in
the present study a significant right ventricular hypertrophy
after MCT+Hx treatment, as previously reported by our
group and others [6, 13] (Fig. 1b). However, our results also
show that mPAP values were surprisingly lower after
4 weeks than after 3 weeks of the protocol. As reported in
human PAH, compensation for right heart failure may be
limited in time, and decompensated right ventricular failure
then occurs, characterized by diastolic dysfunction and re-
duced cardiac output [14, 15]. These mechanisms lead to
lower mPAP values, as observed in our experiments after
4 weeks of the protocol. To confirm this hypothesis, experi-
ments have been conducted to investigate the right heart
function. Functional magnetic resonance imaging evaluated
right heart ejection fraction (EF%), using the Simpson’s rule
[16]. Our results showed a significant decrease of EF% after
4 weeks of our protocol compared with control animals
(Fig. 1c). Such significant decrease was not observed after
3 weeks. These results were confirmed by another tech-
nique (pressure-volume loop analysis) showing values of
EF% significantly lower after 4 weeks of our protocol com-
pared with values of EF% at 3 weeks (data not shown).
These results suggest that our model combining MCT
administration with 4 weeks of Hx may therefore be an
interesting model of severe PAH, mimicking an advanced
stage of the disease.
Complementary to hemodynamic disturbances, struc-
tural and functional alterations of pulmonary arteries in
human PAH include inflammation, altered reactivity and
intense remodeling with a characteristic arteriopathy
including thrombotic, neointimal and plexiform lesions
[4, 17]. In the previous model combining MCT adminis-
tration with 3 weeks of Hx, perivascular inflammatory
infiltrates were previously evidenced [6]. We further
characterized pulmonary arterial inflammation in the
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Fig. 2 Evaluation of intrapulmonary arterial contraction in pulmonary arterial hypertension models. Contractions of rat intrapulmonary arterial
rings induced by cumulative concentrations of phenylephrine (PHE, 10−11 to 10−5M, a), or of prostaglandin F2α (PGF2α, 10−9 to 10−4M, b).
Contractions were studied ex vivo after sacrifice at Day 28 in control rats (CTRL), after chronic hypoxia (Hx), after monocrotaline treatment (MCT),
of after combination of MCT and 4 weeks of Hx (MCT + Hx). Results are expressed as the percentage of maximal contraction and are presented as
means ± SEM with n = 12–15 rats per group. Determination of statistically significant differences between concentration-response curves was
assessed with a two-way analysis of variance. ***p < 0.001 versus control concentration-response curves. ###p < 0.001 versus Hx concentration-
response curves. $$$p < 0.001 versus MCT concentration-response curves. Values of -Log EC50 (half maximal effective concentrations, means ± SEM)
are shown in Table c
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present model by showing increased levels of the pro-
inflammatory cytokines interleukin-1β and tumor necro-
sis factor-α released by pulmonary arteries in the MCT
+Hx group compared to control animals (Fig. 1d and e).
Increased secretion of such pro-inflammatory cytokines
has been previously shown in PAH patients [18], with
cytokine levels being predictive of outcome in these
patients [19, 20]. Reproducing such increase in this ex-
perimental model may therefore be of valuable import-
ance in terms of evaluating PAH severity and outcomes.
We also evaluated, for the first time in MCT +Hx rats,
pulmonary arterial reactivity by dissecting intrapulmonary
arteries from the left lung and mounting them in isolated
organ baths, as previously described [12]. Our results
show that pulmonary arteries from the MCT +Hx group
displayed hyperreactivity to phenylephrine or to prosta-
glandin F2α (PGF2α), and that this hyperreactivity was
even significantly greater compared to that in MCT and/
or Hx groups (Fig. 2). In PAH, a resting vasoconstriction
of pulmonary arteries contributes to the reduction in
vascular caliber [21]. Altered reactivity of pulmonary ar-
teries to vasoconstrictors such as endothelin-1, serotonin,
angiotensin II, phenylephrine or PGF2α has been well
documented in animal models of PH, in particular those
induced by Hx or by MCT [12, 22, 23]. We show, in this
study, that the model combining MCT administration to
4 weeks of Hx also reproduces and amplifies this aspect of
PAH pathophysiology, and may therefore be helpful to
further characterize the pathophysiological mechanisms of
pulmonary arterial altered reactivity.
Finally, since there is no curative options in PAH today,
many studies currently focus on pulmonary arterial
remodeling to define new potential therapeutic targets
[17, 24]. In patients with PAH, this remodeling includes
pulmonary arterial medial hypertrophy and luminal occlu-
sion, as well as concentric laminar and non-laminar
intimal fibrosis, eccentric, plexiform and thrombotic le-
sions [4, 17]. In the MCT +Hx group, pulmonary arteries
displayed classical pathophysiological aspects of PAH, i.e.
pulmonary arterial medial thickening (Fig. 3a and b) and
luminal occlusion (Fig. 3a and c) [6]. We also confirmed
the presence of plexiform-like lesions in our model (Fig. 3d
1 to 5), as previously suggested [6]. Interestingly, as
described in the Sugen model [9] and by Morimatsu [6],
stalk-like plexiform-like complex lesions formed within
the blood lumen were observed in the MCT +Hx model
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Fig. 3 Evaluation of pulmonary arterial remodeling in severe PAH rats. a-c Remodeling of rat pulmonary arteries (less than 50 μm in diameter)
after chronic hypoxia (Hx), after monocrotaline treatment (MCT), or in rats treated with MCT and exposed to 4 weeks of Hx (MCT + Hx), compared
to control rats (CTRL). a Representative cross-sectional views of remodeled pulmonary microarteries (1: CTRL; 2: Hx; 3: MCT; 4: MCT + Hx) showing
medial thickening and luminal occlusion (van Gieson staining). b Percentage of medial thickness. c Luminal occlusion score. For b) and c), results
are presented as means ± SEM with n = 7–11 rats per group. Determination of statistically significant differences was assessed with a one-way
analysis of variance followed by a Dunn test. **p < 0.01 and ***p < 0.001 versus control. ##p < 0.01 versus Hx. For a) scale bars represent 10 μm. d
Representative cross-sectional views of lesions observed in small pulmonary arteries of rats treated with MCT and exposed to 4 weeks of Hx. 1–5:
pulmonary arterial plexiform-like lesions (stalk-like lesions) (1: picro-Mallory staining; 2–5: hematoxylin and eosin staining). 6: pulmonary arterial
thrombotic lesion (Picro-Mallory staining). 7: pulmonary arterial eccentric lesion (hematoxylin and eosin staining). 8–11: concentric cellular
neointimal lesions in pulmonary microarteries (8: hematoxylin and eosin staining, 9: α-smooth muscle actin and 10–11: von Willebrand factor
immunostainings). Scale bars represent 20 μm
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(Fig. 3d 1-5). Plexiform lesions observed in human severe
PAH are difficult to reproduce in animal models. How-
ever, in accordance with our results, some complex
lesions, although not reproducing all pathophysiological
aspects of human lesions, have been described in other
PAH animal models [8, 9], and have also been termed
“plexiform-like lesions”. In the complex lesions observed
in our model, medial hypertrophy and injured endothe-
lium can be seen. However, the angioproliferative aspect
of human plexiform lesions is not reproduced.
We also confirmed the presence of thrombotic lesions
(Fig. 3d 6). Thrombotic occlusions have also been observed
in other PH models induced by Hx and/or Sugen [25], and
are often observed in several forms of human PAH. Al-
though it may be difficult to distinguish between throm-
botic lesions and post-mortem coagulation, thrombotic
lesions observed in our experiments were observed in
PAH rats but not in control animals, suggesting that such
thrombosis may rather be caused by the disease itself.
Finally, for the first time in this MCT +Hx model, we
also showed the presence of other characteristic human-
like lesions. In particular, eccentric lesions were observed
(Fig. 3d 7). Although being often difficult to distinguish,
such eccentric lesions have also been reported in human
PAH and in other PH animal models [26].
In addition, concentric non-laminar intimal thickening le-
sions were also observed (Fig. 3e 8-11), similar to those ob-
served in human severe PAH [4]. A further characterization
of these lesions showed positive staining for α-smooth
muscle actin (Fig. 3d 9) but negative staining for the von
Willebrand factor (Fig. 3d 10-11). This suggests predomin-
ance of smooth muscle cells and/or myofibroblasts rather
than endothelial cells in these lesions, in accordance with
observations of such lesions in human PAH [4, 27].
If classical characteristics of pulmonary arterial remod-
eling, i.e. medial thickening and luminal occlusion, are
easily reproduced in classical models of PAH such as
MCT treatment, other severe PAH specific lesions are
not observed in these models. This explains the need for
developing alternative models more closely related to
human PAH pathophysiology. Models such as pneumon-
ectomy associated to MCT injections [7, 8], or the Sugen
model [9], lead to lesions very close to the pulmonary
arteriopathy observed in human severe PAH. The
present model combining MCT and 4 weeks of Hx may
be a valuable alternative model, with a protocol realized
in a reasonable time and without requiring surgical
skills. Nevertheless, this model involves hypoxia cham-
bers that are not available in all laboratories.
In conclusion, we show here that combining MCT
injection with 4 weeks of exposure to chronic hypoxia in
rats generates a relevant model to the pathogenesis of hu-
man severe PAH. In particular, it reproduces multiple
structural and functional alterations of pulmonary arteries,
including inflammation, altered reactivity and intense re-
modeling. Moreover, this model displays a pulmonary
arteriopathy with thrombotic, severe intimal lesions and
some plexiform-like lesions, similar to those observed in
human severe PAH. As human samples of PAH are diffi-
cult to obtain, the present model, using classical protocols
performed in one month, may therefore be valuable to
further understand the pathophysiology of severe PAH.
According to the current recommendations on PAH
translational research suggesting the use of more than one
rodent model [28], using this model together with other
models of severe PAH may also be of interest to identify
new potential therapeutic targets in this disease.
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